Neuropace Inc
NPCE
$12.99
Closing
▼-4.20%
1D
▲25.99%
YTD
Market cap
$373.07M
52 week high
$18.01
52 week low
$3.83
Volume
15,067
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$373.07M
Analysts' Rating
BUY
Price Target (Mean)
9.5
Total Analysts
5
P/E
Operating Margin
-36.22%
Beta
Revenue Growth (Annual)
0.75%
52 week high
$18.01
52 week low
$3.83
Div. Yield
%
EPS Annual Growth
-22.22
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
NeuroPace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s differentiated RNS System is a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company is developing its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. RNS System is a device that records brain activity data and allows clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
